All type of patients: 12 trials - Ristic - Marre - Li - Li - Horton - Hanefeld - Saloranta - Mari - Goldberg - Jovanovic - Bech - Moses
| nateglinide vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nateglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nateglinide vs repaglinide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| repaglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All types of patients: 12 trials - Ristic - Marre - Li - Li - Horton - Hanefeld - Saloranta - Mari - Goldberg - Jovanovic - Bech - Moses
| nateglinide vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nateglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| nateglinide vs repaglinide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| repaglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 1 trials - Ristic
| nateglinide vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 1 trials - Ristic
| nateglinide vs gliclazide (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
People with impaired glucose tolerance: 1 trials - NAVIGATOR nateglinide
| nateglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | 0.95 [0.82 1.10] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | Cardiovascular death | 1.07 [0.83 1.38] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | myocardial infarction (fatal and non fatal) | 0.95 [0.75 1.20] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | stroke (fatal and non fatal) | 0.88 [0.68 1.14] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | cardiovascular death, MI, stroke | no data | | Diabetes | 1.06 [0.98 1.16] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | hospitalisation for heart failure | 0.85 [0.64 1.14] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | All cause death | 1.00 [0.85 1.17] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - NAVIGATOR nateglinide
| nateglinide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | 0.95 [0.82 1.10] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | Cardiovascular death | 1.07 [0.83 1.38] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | myocardial infarction (fatal and non fatal) | 0.95 [0.75 1.20] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | stroke (fatal and non fatal) | 0.88 [0.68 1.14] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | cardiovascular death, MI, stroke | no data | | Diabetes | 1.06 [0.98 1.16] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | hospitalisation for heart failure | 0.85 [0.64 1.14] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, | | All cause death | 1.00 [0.85 1.17] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR nateglinide, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
